Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Change in Receivables (2018 - 2025)

Historic Change in Receivables for Fate Therapeutics (FATE) over the last 7 years, with Q3 2025 value amounting to -$713000.0.

  • Fate Therapeutics' Change in Receivables fell 12876.16% to -$713000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.4 million, marking a year-over-year decrease of 27320.26%. This contributed to the annual value of $1.1 million for FY2024, which is 10303.65% up from last year.
  • Fate Therapeutics' Change in Receivables amounted to -$713000.0 in Q3 2025, which was down 12876.16% from -$1.0 million recorded in Q2 2025.
  • In the past 5 years, Fate Therapeutics' Change in Receivables ranged from a high of $28.3 million in Q4 2022 and a low of -$25.0 million during Q1 2023
  • Its 5-year average for Change in Receivables is -$286000.0, with a median of -$713000.0 in 2025.
  • As far as peak fluctuations go, Fate Therapeutics' Change in Receivables soared by 197010.99% in 2022, and later plummeted by 137320.44% in 2023.
  • Quarter analysis of 5 years shows Fate Therapeutics' Change in Receivables stood at $1.4 million in 2021, then skyrocketed by 1970.11% to $28.3 million in 2022, then plummeted by 98.98% to $288000.0 in 2023, then tumbled by 304.17% to -$588000.0 in 2024, then decreased by 21.26% to -$713000.0 in 2025.
  • Its last three reported values are -$713000.0 in Q3 2025, -$1.0 million for Q2 2025, and -$1.1 million during Q1 2025.